News Articles

Boehringer Ingelheim and MD Anderson form unique Virtual Research and Development Center to rapidly advance new cancer... INGELHEIM, Germany -Monday 12 August 2019

(BUSINESS WIRE)-- Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers. The establishment of...

Updated real-world data shows Giotrif®/Gilotrif® (afatinib) followed by osimertinib... -Friday 2 August 2019

• Sequential afatinib and osimertinib was associated with encouraging time on treatment and overall survival in patients with EGFR T790M-positive NSCLC, especially in patients with Del19 mutation • Updated analysis of the observational GioTag study is published today in Future...

Boehringer Ingelheim and University of Dundee Highlight Successful PROTAC Drug Discovery Program and Extend Their... -Tuesday 11 June 2019

Boehringer Ingelheim and University of Dundee achieve milestone in collaboration aimed at developing novel protein degradation medicines Results published in Nature Chemical Biology showcase the use of the broadly applicable structure-based PROTAC design approach to discover highly potent...

Network of 1,500 Stroke-Ready Clinics across Europe -Thursday 23 May 2019

(BUSINESS WIRE)-- The Angels Initiative announced today at the European Stroke Organisation Conference (ESOC) 2019 in Milan that their three-year goal to create a network of 1,500 stroke-ready centres and hospitals across Europe has been achieved. The Angels Initiative is a unique healthcare...

Phase III study showed nintedanib slows the loss of pulmonary function in people living with systemic sclerosis... -Monday 20 May 2019

Results of pivotal Phase III SENSCIS® trial published today in the New England Journal of Medicine (NEJM) and presented at the American Thoracic Society Conference in Dallas, USA Interstitial lung disease (ILD) is a key driver of mortality in people living with systemic sclerosis (SSc) –...

Financial year 2018: Boehringer Ingelheim grows and invests -Wednesday 17 April 2019

(BUSINESS WIRE)-- The research-driven pharmaceutical company Boehringer Ingelheim ended 2018 with net sales of 17.5 billion euros. Adjusted for currency effects, as well as one-off effects due to the asset swap with Sanofi in 2017, net sales grew by 4 per cent. At 3.2 billion euros (+2.8%), R&D...

Independent large real-world study comparing NOACs in AF-patients -Tuesday 16 April 2019

A recently published large retrospective comparative study investigated stroke, bleeding and mortality risks in older US Medicare patients treated with commonly marketed oral anticoagulants for non-valvular atrial fibrillation1 Results of the real-world study showed that Pradaxa®...

New post-hoc analysis of EMPA-REG OUTCOME® examined cost-effectiveness of empagliflozin versus standard... -Monday 15 April 2019  

Empagliflozin, in addition to standard of care, has the potential to improve economic outcomes for people with type 2 diabetes and established cardiovascular disease who also have diabetic kidney disease, from a US payer perspective1 Cost effective analysis used modeling and simulations...

Boehringer Ingelheim Launches the First-Ever Registered Stem Cell-Based Veterinary Medicine -Tuesday 9 April 2019  

(BUSINESS WIRE)-- Boehringer Ingelheim launches Arti-Cell® Forte in Europe for the ‘reduction of mild to moderate recurrent lameness associated with non-septic joint inflammation in horses’. Equine lameness is truly common and impacts horse performance as well as equine welfare1. Current...

Boehringer Ingelheim Enhances Oncology R&D with Novel MacroDel Delivery Technology Via Acquisition of ICD... -Friday 29 March 2019

New molecular platform to access intracellular targets across a broad range of tumor cell types Opens up new range of therapeutic opportunities for difficult-to-treat cancers (BUSINESS WIRE)-- Boehringer Ingelheim today announced that it acquired ICD Therapeutics. The acquisition...

Initial results from the EMPRISE real-world study of empagliflozin compared with DPP-4 inhibitors presented at ACC.19... -Thursday 28 March 2019  

(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced initial results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) real-world evidence study that show that empagliflozin is associated with a 22 percent relative risk reduction in all-cause...

Boehringer Ingelheim's novel antibody shows potential to transform treatment of rare form of psoriasis -Thursday 7 March 2019

(BUSINESS WIRE)-- The New England Journal of Medicine (NEJM) today published new data from a Phase I clinical trial showing BI 655130, a first-in-class investigational treatment, significantly improved symptoms of generalised pustular psoriasis (GPP), a rare form of psoriasis.1 BI 655130 is a...

Vargatef® plus docetaxel could be an option after failure of immunotherapy in lung cancer -Friday 14 December 2018

(BUSINESS WIRE)-- Boehringer Ingelheim announced today the first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and safety of Vargatef® (nintedanib) and docetaxel in patients with stage III/IV locally advanced or...

Initial results from EMPRISE real-world evidence study shows empagliflozin was associated with reduced risk for... -Monday 5 November 2018  

(BUSINESS WIRE)-- Initial effectiveness results from the real-world EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study showed empagliflozin was associated with a 44 percent relative risk reduction in hospitalisation for heart failure (HHF) compared with dipeptidyl peptidase-4...

Boehringer Ingelheim and Lilly present full results of Trajenta®’s... -Thursday 4 October 2018  

(BUSINESS WIRE)-- Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) today presented the full results of the long-term cardiovascular outcome trial, CARMELINA®, which studied the impact of Trajenta® (linagliptin) on cardiovascular and kidney safety in adults with type 2 diabetes at...

Boehringer Ingelheim and Lilly present full results from EASE Phase III programme for empagliflozin as adjunct to... -Thursday 4 October 2018  

All investigated doses met the primary efficacy endpoint defined as a change from baseline in HbA1c versus placebo after 26 weeks of treatment Regulatory discussions initiated for empagliflozin, as adjunct to insulin, in type 1 diabetes Full results presented at the 54th European...

Large European real-world study reports effects of Spiolto® Respimat® for people... -Monday 17 September 2018

(BUSINESS WIRE)-- Boehringer Ingelheim announced results from the OTIVACTO study, an observational European real-world study of 7,443 Chronic Obstructive Pulmonary Disease (COPD) patients treated with Spiolto® (tiotropium/olodaterol) Respimat®, which were presented today at the European...

Clinical trial data for nintedanib in patients with advanced IPF published -Sunday 16 September 2018  

INSTAGE® trial results published in the New England Journal of Medicine1 Trial provides clinical data on patients with IPF and severe impairment in gas exchange usually excluded from clinical trials1 Efficacy and safety profile of nintedanib in patients with advanced IPF was...

New study results provide evidence that Ofev® (nintedanib) slows progression of IPF beyond four years... -Saturday 15 September 2018

INPULSIS®-ON study indicates safety and efficacy of Ofev® (nintedanib) are maintained over the long term and consistent with prior findings from INPULSIS® trials1 Results from INPULSIS®-ON, the open-label extension from the two INPULSIS® Phase III trials, published in Lancet...

Boehringer Ingelheim Acquires All ViraTherapeutics Shares to Develop Next Generation Viral-Based Immuno-Oncology... -Thursday 13 September 2018

Boehringer Ingelheim exercises its option to acquire all shares of oncolytic virus company ViraTherapeutics ViraTherapeutics will operate in Innsbruck, Austria as a distinct unit of Boehringer Ingelheim’s Discovery Research organization, maintaining its innovative biotech heritage and...